This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AstraZeneca's Asthma Candidate Shows Promising Results
by Zacks Equity Research
AstraZeneca's asthma candidate, benralizumab, showed promising results in patients who experience more frequent exacerbations despite being on standard-of-care medicines.
AstraZeneca's Lung Cancer Study Data Promising, Shares Spike
by Zacks Equity Research
AstraZeneca, (AZN) releases data from a late-stage study on Imfinzi which showed that the new cancer drug led to superior progression-free survival to standard of care in lung cancer patients.
Foreign Stock Roundup: HMC Agrees on $605M Takata Air Bag Settlement, Narasimhan to Head Novartis
by Swarup Gupta
North Korea-related tensions weighed on stocks across the world last week.
Company News For Sep 8, 2017
by Zacks Equity Research
Companies in the news are: RH,AZN,GOOGL,CONN
Celgene (CELG) Fusion Program Studies Put on Hold by FDA
by Zacks Equity Research
Celgene Corporation (CELG) announced that the FDA put a hold on several trials in the FUSION program evaluating Imfinzi, an anti-PD-L1 antibody, in combination with immunomodulatory and chemotherapy agents in blood cancers.
AstraZeneca (AZN) Looks Good: Stock Adds 5.1% in Session
by Zacks Equity Research
AstraZeneca (AZN) shares rose more than 5% in the last trading session, amid huge volumes.
Pharma Stock Roundup: Lilly to Cut Jobs, Streamline Operations, NVS CEO to Step Down in 2018
by Arpita Dutt
Key highlights this week include Eli Lilly and Company's (LLY) decision to cut the work force and streamline operations and Merck's efforts to strengthen its immune-oncology franchise.
Bristol-Myers' (BMY) Opdivo's Myeloma Studies Put on Hold
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) announced that the FDA put a partial clinical hold on three clinical trials, investigating Opdivo-based combinations in patients with relapsed or refractory multiple myeloma.
Amgen/AstraZeneca Asthma Candidate Tezepelumab Shows Promise
by Zacks Equity Research
Amgen (AMGN) and AstraZeneca (AZN) announced promising data from a phase IIb study on tezepelumab, which reduced the rate of deterioration of asthma in patients with severe uncontrolled asthma.
Merck (MRK) Opts for Buying German Immuno-Oncology Biotech
by Zacks Equity Research
Merck (MRK) to acquire Germany-based Rigontec, a leader in retinoic acid-inducible gene I (RIG-I), a novel immuno-oncology treatment approach targeting therapeutics.
AstraZeneca's COPD Candidate Duaklir Reports Positive Data
by Zacks Equity Research
AstraZeneca Plc (AZN) announced encouraging results from the phase III AMPLIFY study for Duaklir being developed for the treatment of chronic obstructive pulmonary disease (COPD).
4 Drug Stocks Worth a Look on Promising Cancer Pipeline
by Zacks Equity Research
Cancer is the second most common cause of death in the U.S. preceded only by heart disease. We discuss four pharma giants, which possess the industry's strongest oncology pipeline portfolios.
Valeant (VRX) Continues to Lose Ground: Can It Bounce Back?
by Zacks Equity Research
Valeant has been caught up in various controversies due to price hike of specialty drugs, erroneous financial reporting and termination of contracts with Philidor Rx Services and woes do not end.
Parkinson's Now a Hot Therapeutic Area: What's Up Lately?
by Zacks Equity Research
Parkinson's disease is a lucrative area due to lack of curative therapy in this space. Many players are trying to bring new treatments to the market. A lot has happened in last couple of months.
Pharma Stock Roundup: Novartis CAR-T Drug Gets FDA Nod, Lilly Gives Baricitinib Update
by Arpita Dutt
It was a landmark week for the pharmaceutical sector and the medical community with the FDA approving Novartis' (NVS) Kymriah, the first CAR-T cell treatment to be approved in the United States.
AstraZeneca and Takeda Ink Deal to Develop Parkinson's Drug
by Zacks Equity Research
AstraZeneca (AZN) and Takeda Pharmaceutical Company entered into an agreement to jointly develop and commercialize MEDI1341 for the potential treatment of Parkinson's disease.
Novo Nordisk's Victoza Gets FDA Nod for Label Expansion
by Zacks Equity Research
Novo Nordisk's (NVO) Victoza receives FDA nod for its label expansion to include cardiovascular events in adult patients with type II diabetes. Shares up.
AstraZeneca's Faslodex Gets FDA Nod in First-Line Setting
by Zacks Equity Research
AstraZeneca (AZN) drug Faslodex receives FDA approval for a label extension for Faslodex in the first-line monotherapy setting for the treatment of advanced breast cancer.
Pharma Stock Roundup: Roche Drug Gets Priority Review, EU Nod for Novartis Drug
by Arpita Dutt
It was a pretty slow week with key highlights including regulatory updates from companies like Roche (RHHBY) and Novartis.
Pfizer's Ibrance in First-Line Combo Breast Cancer Study
by Zacks Equity Research
Pfizer, Inc. (PFE) and six international cancer research groups are collaborating on a combination study to explore the use of Ibrance for first-line treatment of advanced breast cancer.
Perrigo's (PRGO) OTC Version of Nexium Secures FDA Approval
by Zacks Equity Research
Perrigo (PRGO) gains an FDA consent for the OTC version of AstraZeneca's Nexium post the ongoing patent lawsuit settlement through an agreement.
Ironwood Pharma's Combination Gout Drug Gets FDA Approval
by Zacks Equity Research
Ironwood Pharmaceuticals, Inc. (IRWD) announced that the FDA has approved Duzallo for the treatment of hyperuricemia in patients with uncontrolled gout.
AstraZeneca/Merck's Lynparza Gets FDA Nod for Label Expansion
by Zacks Equity Research
AstraZeneca, plc (AZN) and partner Merck's ovarian cancer drug, Lynparza has received FDA approval for new tablet formulation and a broader U.S. label.
Pharma Stock Roundup: Multiple Sclerosis Drug Prices in Focus, Mixed Data on BMY's Opdivo
by Arpita Dutt
Key highlights this week in the pharmaceutical sector include the launch of a drug pricing probe, a resignation from the President's manufacturing council and data on Bristol-Myers' (BMY) Opdivo.
Can Pfizer Bank on New Immunotherapy Bavencio for Growth?
by Zacks Equity Research
Pfizer, Inc.'s (PFE) newly approved anti-PD-L1 immunotherapy, Bavencio, is being touted as a significant top-line driver for this New York-based pharma giant.